Verapamil hci formulation and other ophthalmic solutions...

Details Verapamil hci formulation and other ophthalmic solutions... Verapamil hci formulation and other ophthalmic solutions...

A - Human Necessities

61

K

A61K 31/275 (2006.01) A61K 9/00 (2006.01) A61K 9/08 (2006.01)

Patent

CA 2102110

2102110 9318764 PCTABS00025 An aqueous ophthalmic solution is disclosed in which one or more acive ingredients in ionized form are gradually brought to undissociated, free base form by lacrimal solution acting against the affect of a plurality of buffers. The affect of each buffer is overcome sequentially by the lacrimal fluid. A preferred formulation includes verapamil HCl as the active ingredient in ionized form and includes as buffers: boric acid at 2.8 %, disodium edetate at 0.18 %, dextrose at 0.3 %, and polyvinylpyrrolidone at 2.0 %.

Affiliated with

Also associated with

Rating

Verapamil hci formulation and other ophthalmic solutions... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Verapamil hci formulation and other ophthalmic solutions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Verapamil hci formulation and other ophthalmic solutions... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1744565